Skip to main content
. 2022 Oct 3;2(10):1104–1118. doi: 10.1158/2767-9764.CRC-22-0117

FIGURE 1.

FIGURE 1

Pharmacologic inhibition of SHP2 inhibits MBC. A, Schematic of the study combining SHP099 with PD-L1 antibodies to treat mice bearing D2.A1 pulmonary tumors. Elements in the scheme were created using BioRender. B, Representative bioluminescent images of pulmonary D2.A1 growth at day 8 and day 20 postinjection. C, Bioluminescent values from pulmonary regions of interest (ROI) quantified as the ratio of day 20 to day 8 postinjection (**, P < 0.01, n  =  5 mice per group). D, Plots comparing the wet lung weights of the mice at day 22 postinjection (**, P < 0.01, n  =  5 mice per group). E, Representative H&E staining of lung histologic sections at day 22 postinjection.